Document Detail


The use of genetic information in large-scale clinical trials: applications to Alzheimer research.
MedLine Citation:
PMID:  8876785     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A great deal of secondary, or covariable, information is often collected during the course of large-scale clinical trials. This information typically includes demographic and anthropometric data but often also includes more elaborate laboratory-based measures that might be used to screen for adverse reactions to the preventive agent or treatment being tested. This information can be and often is used to identify individuals or, more likely, subgroups of individuals who appear to respond better (or worse) to the compound of relevance. Such heterogeneity in response is to be expected, since the basic biological constitution of individuals differs widely and since it is well known from simple pharmacokinetic assays that such differences can affect drug responses. Since genes influence the biological constitution of individuals, it is easy to argue that genetic differences between individuals could explain differential responsiveness to certain drugs, as pharmacogeneticists have suggested for years. In this article, it is argued that by collecting relevant genetic data on participants in large-scale clinical trials as though these data merely provided additional covariables, one might not only be in a position to identify responders and nonresponders to the compound being tested but could also be in a position to address fundamental questions about the nature and pathogenesis of the disease for which the compound was designed. Although we exemplify this simple argument by referring to antihypertensive compounds and research, this reference is made merely for reasons of convenience, since there are numerous compounds designed expressly for the prevention and treatment of hypertension, but rather few for Alzheimer disease. It is hoped that by adopting some of the guidelines and principles outlined herein, better and more appropriate compounds for the prevention and treatment of Alzheimer disease will be tested and ultimately made available to the patients for whom they work best.
Authors:
N J Schork; A B Weder
Related Documents :
9192445 - Bayesian design and analysis of two x two factorial clinical trials.
11169595 - Mid-trial design reviews for sequential clinical trials.
17914715 - Controlling the type 1 error rate in non-inferiority trials.
9004395 - Mixture models for the joint distribution of repeated measures and event times.
23193235 - Activity recognition using mixture of vector fields.
19572405 - Multiobjective flux balancing using the nise method for metabolic network analysis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Alzheimer disease and associated disorders     Volume:  10 Suppl 1     ISSN:  0893-0341     ISO Abbreviation:  Alzheimer Dis Assoc Disord     Publication Date:  1996  
Date Detail:
Created Date:  1997-01-16     Completed Date:  1997-01-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8704771     Medline TA:  Alzheimer Dis Assoc Disord     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  22-6     Citation Subset:  IM    
Affiliation:
Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Alzheimer Disease / genetics*
Clinical Trials as Topic
Humans
Hypertension / genetics*
Research Design*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Approaches to the prevention of Alzheimer disease.
Next Document:  Statistical issues in prevention and therapeutic trials of Alzheimer disease.